Denver-based market research startup GutCheck has found $4 million for a Series B round of financing.
Slow-moving regulators have kept the rules of engagement on social media platforms fuzzy for pharma players. Yet rather than sit on the sidelines waiting for the FDA to take a firm stance on dos and don'ts, many pharma companies have taken a shot at safe moves in the social realm. Potentially powerful collaboration tools have also attracted pharma groups, bringing scientists, patients and physicians into the same digital arenas to share ideas and partner on research. Read the report >>
Global consulting firm InVentiv Health has struck a partnership with the social analytics startup Medikly, believing that young company's technology gives it an edge in assisting its clients with finding physicians to participate in clinical research.
Bill Gates has added his high-profile name and dollars to the open-science movement.
Bill Gates has added his high-profile name and dollars to the open-science movement, joining other investors in a $35 million financing round for the 5-year-old social network for scientists called ResearchGate.
Eli Lilly has invested more in digital overtures to cancer specialists. The pharma giant has sponsored a mobile app for iPhone and Android devices that provides reviews of journal articles, aiming to help keep busy physicians abreast of the latest research in their areas of specialty or interest.
Sanofi has gone online in search of patients for clinical trials, partnering with the social network PatientsLikeMe and a healthcare nonprofit to inform patients about trials and match them with appropriate studies from the French drug giant.
Merck's U.K. group has raised its level of play in an industry-wide competition for the attention of physicians as they use the Internet.
To understand why parents balk at routine vaccinations for their kids, GlaxoSmithKline undertook a project to mine parent websites with text analytics software from an MIT spinoff. The project has led the drugmaker to reconsider how it helps physicians communicate with parents about inoculating their children.
GlaxoSmithKline has been listening to parents' concerns about childhood vaccinations. Really listening. In fact, it has used big data analytics to sift through thousands of comments from Internet chat forums to try to get a better grasp of exactly what objections there are and how to best face them.